Brisdelle FDA Approval History
FDA Approved: Yes (First approved June 28, 2013)
Brand name: Brisdelle
Generic name: paroxetine mesylate
Dosage form: Capsules
Company: Noven Pharmaceuticals, Inc.
Treatment for: Postmenopausal Symptoms
Brisdelle (paroxetine mesylate) is a low-dose selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Development Timeline for Brisdelle
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.